MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression

Li Bing1, Chen Hong, Shang Li-Xin

  • 1Department of Gynecology and Obstetrics, The Military General Hospital of Beijing PLA, Beijing, 100700, China.

Abstract

Insights

MicroRNA-543 (miR-543) acts as a tumor suppressor in endometrial cancer by targeting focal adhesion kinase (FAK) and Twist homolog 1 (TWIST1). Lower miR-543 levels correlate with increased FAK and TWIST1, promoting cancer progression.

Area of Science:

  • Molecular oncology
  • Cancer biology
  • Gene regulation

Background:

  • Focal adhesion kinase (FAK) and Twist homolog 1 (TWIST1) are oncogenes implicated in tumor progression, metastasis, and poor survival.
  • Elevated FAK and TWIST1 expression are observed in various solid human tumors.

Purpose of the Study:

  • To investigate the role of miR-543 as a regulator of FAK and TWIST1 in endometrial cancer.
  • To determine the functional impact of miR-543 on endometrial cancer cell behavior.

Main Methods:

  • Utilized endometrial cancer cell lines for functional studies.
  • Assessed the effects of forced miR-543 expression on FAK and TWIST1 mRNA and protein levels.
  • Evaluated the impact of miR-543 on cancer cell proliferation, anchorage-independent growth, migration, and invasion.
  • Compared miR-543 expression in malignant versus normal endometrial tissues.

Main Results:

  • Forced miR-543 expression reduced endogenous FAK and TWIST1 levels in endometrial cancer cells.
  • Overexpression of miR-543 inhibited endometrial cancer cell proliferation, anchorage-independent growth, migration, and invasion.
  • Endogenous miR-543 levels were decreased in malignant endometrial tissues compared to normal tissues.
  • miR-543 levels inversely correlated with FAK and TWIST1 mRNA levels in endometrial cancer.

Conclusions:

  • miR-543 functions as a tumor suppressor in endometrial cancer.
  • miR-543 targets FAK and TWIST1, thereby inhibiting endometrial cancer progression.
  • Decreased miR-543 expression is a characteristic of endometrial cancer and is associated with increased FAK and TWIST1.